• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Stoke Therapeutics Inc (NQ: STOK )

    12.86 +0.50 (+4.05%)
    Streaming Delayed Price Updated: 3:06 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Stoke Therapeutics Inc

    < Previous 1 2 3 Next >
    Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present at Upcoming Investor Conferences in September
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present at Upcoming Investor Conferences in June
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Proposed Public Offering
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Inc. (NASDAQ: STOK) Near the Top of Equities by Percentage Gain on 3/26
    Via Investor Brand Network
    Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Appoints Ian Smith to its Board of Directors
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.